Kodiak Sciences (NASDAQ:KOD) Director Purchases $15,826,419.58 in Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker acquired 160,658 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were bought at an average price of $98.51 per share, for a total transaction of $15,826,419.58. Following the acquisition, the director directly owned 20,343,130 shares of the company’s stock, valued at approximately $2,004,001,736.30. This trade represents a 0.80% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Thursday, November 5th, Bros. Advisors Lp Baker acquired 86,432 shares of Kodiak Sciences stock. The shares were bought at an average cost of $98.51 per share, for a total transaction of $8,514,416.32.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock. The stock was purchased at an average price of $72.57 per share, with a total value of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 418,323 shares of Kodiak Sciences stock. The stock was purchased at an average price of $83.58 per share, with a total value of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker bought 33,726 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $85.05 per share, with a total value of $2,868,396.30.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 681,866 shares of Kodiak Sciences stock. The shares were purchased at an average cost of $88.77 per share, for a total transaction of $60,529,244.82.

Kodiak Sciences Trading Up 9.1%

KOD stock traded up $8.28 during trading on Friday, reaching $99.30. 1,038,739 shares of the stock were exchanged, compared to its average volume of 1,128,011. The firm’s 50 day moving average is $68.36 and its 200 day moving average is $43.32. The firm has a market cap of $6.24 billion, a P/E ratio of -23.70 and a beta of 2.02. Kodiak Sciences Inc. has a twelve month low of $15.83 and a twelve month high of $104.00.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). As a group, analysts predict that Kodiak Sciences Inc. will post -3.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kodiak Sciences

A number of hedge funds have recently added to or reduced their stakes in KOD. V Square Quantitative Management LLC bought a new stake in Kodiak Sciences during the 1st quarter worth approximately $26,000. KBC Group NV purchased a new stake in shares of Kodiak Sciences in the first quarter worth approximately $39,000. Sterling Capital Management LLC lifted its holdings in shares of Kodiak Sciences by 850.0% in the third quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock valued at $124,000 after purchasing an additional 1,173 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Kodiak Sciences by 94.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock valued at $73,000 after acquiring an additional 936 shares in the last quarter. Finally, Simplicity Wealth LLC bought a new position in shares of Kodiak Sciences during the third quarter valued at about $263,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on KOD shares. Wall Street Zen upgraded Kodiak Sciences from a “strong sell” rating to a “sell” rating in a report on Sunday, October 4th. UBS Group boosted their price target on shares of Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, September 28th. The Goldman Sachs Group started coverage on shares of Kodiak Sciences in a research note on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target for the company. HC Wainwright upped their price objective on shares of Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Finally, Lifesci Capital raised their price objective on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.71.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.